PDCD1 and non-small cell lung carcinoma: Conversely, a high abundance of Proteobacteria is associated with reduced efficacy of immunotherapy, and Helicobacter pylori seropositivity correlates with poorer survival in NSCLC patients receiving anti-PD-1 therapy (124).